Literature DB >> 8939223

Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study.

T de Baere1, X Zhang, B Aubert, G Harry, C Lagrange, J Ropers, J Dufaux, J Lumbroso, P Rougier, M Ducreux, A Roche.   

Abstract

PURPOSE: To optimize use of iodized oil for diagnostic computed tomography (CT) enhanced with iodized oil and for interstitial radiation therapy with iodine-131-labeled iodized oil, the authors quantified the distribution of iodized oil after injection of different formulations of iodized oil into the hepatic artery.
MATERIALS AND METHODS: I-125-labeled iodinated ethyl ester of poppyseed oil in two viscosities (iodized oil ultrafluid [viscosity, 0.04 Pa/sec] and iodized oil fluid [viscosity, 0.17 Pa/sec]) was injected (pure forms and three different emulsions of each) into the hepatic artery of rabbits bearing VX2 tumors in the liver. All rabbits received a radiation dose of 4 MBq per kilogram of body weight in 0.1 mL/kg iodized oil. Animals were killed 4 days later, and iodized oil uptake was evaluated in the tumor, nontumorous liver, and lung.
RESULTS: There were no statistically significant differences in uptake between pure iodized oil ultrafluid or fluid or between the same type of emulsions made with each type of iodized oil. Lung uptake was significantly higher with pure iodized oil ultrafluid and fluid (19.75 kBq/g +/- 3.25 [standard error of the mean] vs 19.48 kBq/g +/- 6.15, respectively) than with any emulsions (range, 3.72-8.14 kBq/g; mean, 5.68 kBq/g) except the small-droplet oil-in-water emulsion (10.51 kBq/g +/- 1.18). The ratio of tumor to nontumorous liver uptake of iodized oil was significantly higher with large-droplet water-in-oil emulsions made of iodized oil ultrafluid or fluid (10.26 +/- 2.88 and 9.53 +/- 0.64, respectively) than with any other product (range, 4.07-5.38; mean, 4.49).
CONCLUSION: Use of large-droplet water-in-oil emulsions limited lung uptake and increased tumor uptake of iodized oil after intraarterial hepatic injection in rabbits bearing VX2 tumors in the liver.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939223     DOI: 10.1148/radiology.201.3.8939223

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

1.  Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.

Authors:  Shiro Miyayama; Masashi Yamashiro; Yoshihiro Shibata; Masahiro Hashimoto; Miki Yoshida; Kazunobu Tsuji; Fumihito Toshima; Osamu Matsui
Journal:  Jpn J Radiol       Date:  2012-01-07       Impact factor: 2.374

Review 2.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

3.  Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin.

Authors:  Frederic Deschamps; Kathleen R Harris; Laurence Moine; Weiguo Li; Lambros Tselikas; Thomas Isoardo; Robert J Lewandowski; Angelo Paci; Nicolas Huang; Thierry de Baere; Riad Salem; Andrew C Larson
Journal:  Cardiovasc Intervent Radiol       Date:  2018-02-21       Impact factor: 2.740

4.  Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.

Authors:  Yuki Tomozawa; Norihisa Nitta; Shinji Ohta; Hideji Otani; Shobu Watanabe; Akinaga Sonoda; Keiko Tsuchiya; Ayumi Nitta-Seko; Masashi Takahashi; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2013-07-05       Impact factor: 2.374

5.  Palliative nonvascular interventions.

Authors:  Kent T Sato; Christopher Takehana
Journal:  Semin Intervent Radiol       Date:  2007-12       Impact factor: 1.513

Review 6.  Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Authors:  Norihiro Imai; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Yoshiki Hirooka; Hidemi Goto
Journal:  World J Hepatol       Date:  2014-12-27

7.  Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.

Authors:  Daniel Coman; Julius Chapiro; Lynn Jeanette Savic; Isabel Theresa Schobert; Dana Peters; John J Walsh; Fabian Max Laage-Gaupp; Charlie Alexander Hamm; Nina Tritz; Luzie A Doemel; MingDe Lin; Albert Sinusas; Todd Schlachter; James S Duncan; Fahmeed Hyder
Journal:  Clin Cancer Res       Date:  2019-10-03       Impact factor: 12.531

8.  Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC).

Authors:  Ricardo Yamada; Beatriz Bassaco; Stephen Bracewell; Kirkpatrick Gillen; Madison Kocher; Heather Collins; Michael Bret Anderson; Marcelo Guimaraes
Journal:  J Gastrointest Oncol       Date:  2019-04

Review 9.  The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Authors:  Sung Wook Shin
Journal:  Korean J Radiol       Date:  2009-08-25       Impact factor: 3.500

10.  Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma.

Authors:  Ricardo Yamada; Beatriz Bassaco; Stephen Bracewell; Samuel Volin; Heather Collins; Christopher Hannegan; Marcelo Guimarares
Journal:  J Gastrointest Oncol       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.